Aggregometry in the settings of thrombocytopenia, thrombocytosis and antiplatelet therapy

References

• Cattaneo M. Inherited platelet-based bleeding disorders. J Thromb Haemost. 2003;1:1628–1636. doi:10.1046/j.1538-7836.2003.00266.x.
   PubMed Web of Science ®Google Scholar
• Cattaneo M. Light transmission aggregometry and ATP release for the diagnostic assessment of platelet function. Semin Thromb Hemost. 2009;35(2):158–167. doi:10.1055/s-0029-1220324.
   PubMed Web of Science ®Google Scholar
• Cattaneo M, Cerletti C, Harrison P, Hayward CP, Kenny D, Nugent D, Nurden P, Rao AK, Schmaier AH, Watson SP, et al. Recommendations for the standardization of light transmission aggregometry: a consensus of the working party from the platelet physiology subcommittee of SSC/ISTH. J Thromb Haemost. 2013;11:1183–1196. doi:10.1111/jth.12231.
   Web of Science ®Google Scholar
• Podda G, Femia EA, Pugliano M, Cattaneo M. Congenital defects of platelet function. Platelets. 2012;23(7):552–563. doi:10.3109/09537104.2012.724737.
   PubMed Web of Science ®Google Scholar
• Pai M, Wang G, Moffat KA, Liu Y, Seecharan J, Webert K, Heddle N, Hayward C. Diagnostic usefulness of a lumi-aggregometer adenosine triphosphate release assay for the assessment of platelet function disorders. Am J Clin Pathol. 2011;136(3):350–358. doi:10.1309/AJCP9IPR1TFLUAGM.
   PubMed Web of Science ®Google Scholar
• Cattaneo M, Lecchi A, Zighetti ML, Lussana F. Platelet aggregation studies: autologous platelet-poor plasma inhibits platelet aggregation when added to platelet-rich plasma to normalize platelet count. Haematologica. 2007;92:694–697. doi:10.3324/haematol.10999.
   PubMed Web of Science ®Google Scholar
• Femia EA, Scavone M, Lecchi A, Cattaneo M. Effect of platelet count on platelet aggregation measured with impedance aggregometry (Multiplate™ analyzer) and with light transmission aggregometry. J Thromb Haemost. 2013;11(12):2193–2196. doi:10.1111/jth.2013.11.issue-12.
   PubMed Web of Science ®Google Scholar
• Dc C, Rj F. The electronic aggregometer: a novel device for assessing platelet behavior in blood. J Pharmacol Methods. 1980;3(2):135–158. doi:10.1016/0160-5402(80)90024-8.
   PubMedGoogle Scholar
• Kong R, Trimmings A, Hutchinson N, Gill R, Agarwal S, Davidson S, Arcari M. Consensus recommendations for using the Multiplate(®) for platelet function monitoring before cardiac surgery. Int J Lab Hematol. 2015;37(2):143–147. doi:10.1111/ijlh.12279.
   PubMed Web of Science ®Google Scholar
• Awidi A, Maqablah A, Dweik M, Bsoul N, Abu-Khader A. Comparison of platelet aggregation using light transmission and multiple electrode aggregometry in Glanzmann thrombasthenia. Platelets. 2009;20(5):297–301. doi:10.1080/09537100903006246.
   PubMed Web of Science ®Google Scholar
• Al Gahiti R, Drake S, Watson SP, Morgan NV, Harrison P. Comparison of multiple electrode aggregometry with lumi-aggregometry for the diagnosis of patients with mild bleeding disorders. J Thromb Haemost. 2017;15:2045–2052. doi:10.1111/jth.13784.
   PubMed Web of Science ®Google Scholar
• Fox SC, Burgess-Wilson M, Heptinstall S, Mitchell JR. Platelet aggregation in whole blood determined using the Ultra-Flo 100 Platelet Counter. Thromb Haemost. 1982;48:327–329.
   PubMed Web of Science ®Google Scholar
• De Cuyper IM, Meinders M, van de Vijver E, de Korte D, Porcelijn L, de Haas M, Eble JA, Seeger K, Rutella S, Pagliara D, et al. A novel flow cytometry-based platelet aggregation assay. Blood. 2013;121(10):e70–80. doi:10.1182/blood-2012-06-437723.
   PubMed Web of Science ®Google Scholar
• Israels SJ. Diagnostic evaluation of platelet function disorders in neonates and children: an update. Semin Thromb Hemost. 2009;35(2):181–188. doi:10.1055/s-0029-1220326.
   PubMed Web of Science ®Google Scholar
• Frelinger AL 3rd, Rf G, Aj G, Berny-Lang MA, Brown T, Carmichael SL, Neufeld EJ, Michelson AD. Platelet function tests, independent of platelet count, are associated with bleeding severity in ITP. Blood. 2015;126(7):873–879. doi:10.1182/blood-2015-02-628461.
   PubMed Web of Science ®Google Scholar
• Mirkhel A, Peyster E, Sundeen J, Greene L, Michelson AD, Hasan A, Domanski M. Frequency of aspirin resistance in a community hospital. Am J Cardiol. 2006;98:577–579. doi:10.1016/j.amjcard.2006.03.029.
   PubMed Web of Science ®Google Scholar
• Malinin A, Pokov A, Swaim L, Kotob M, Serebruany V. Validation of a VerifyNow-P2Y12 cartridge for monitoring platelet inhibition with clopidogrel. Methods Find Exp Clin Pharmacol. 2006;28:315–322. doi:10.1358/mf.2006.28.5.990205.
   PubMed Web of Science ®Google Scholar
• von Beckerath N, Pogatsa-Murray G, Wieczorek A, Sibbing D, Schomig A, Kastrati A. Correlation of a new point-of-care test with conventional optical aggregometry or the assessment of clopidogrel responsiveness. Thromb Haemost. 2006;95:910–911.
   PubMed Web of Science ®Google Scholar
• van Werkum JW, van der Stelt CA, Seesing TH, Hackeng CM, ten Berg JM. A. head-to-head comparison between the VerifyNow P2Y12 assay and light transmittance aggregometry for monitoring the individual platelet response to clopidogrel in patients undergoing elective percutaneous coronary intervention. J Thromb Haemost. 2006;4:2516–2518. doi:10.1111/j.1538-7836.2006.02187.x.
   PubMed Web of Science ®Google Scholar
• Kim YG, Suh JW, Sibbing D, Kastrati A, Ko YG, Jang Y, Cho YS, Youn TJ, Chae IH, Choi DJ, et al. A laboratory association between hemoglobin and VerifyNow P2Y12 reaction unit: a systematic review and meta-analysis. Am Heart J. 2017;188:53–64. doi:10.1016/j.ahj.2017.03.006.
   PubMed Web of Science ®Google Scholar
• Vinholt PJ, Frederiksen H, Hvas A-M, Sprogoe U, Nielsen U. Measurement of platelet aggregation, independently of patients platelet count: a flow-cytometric approach. J Thromb Haemost. 2017;15:1191–1202. doi:10.1111/jth.13675.
   PubMed Web of Science ®Google Scholar
• van Bladel ER, Laarhoven AG, van der Heijden LB, Heitink-Pollé KM, Porcelijn L, van der Schoot CE, de Haas M, Roest M, Vidarsson G, de Groot PG, et al. Functional platelet defects in children with severe chronic ITP as tested with 2 novel assays applicable for low platelet counts. Blood. 2014;123(10):1556–1563. doi:10.1182/blood-2013-08-519686.
   PubMed Web of Science ®Google Scholar
• Psaila B, Bussel JB, Frelinger AL, Babula B, Linden MD, Li Y, Barnard MR, Tate C, Feldman EJ, Michelson AD. Differences in platelet function in patients with acute myeloid leukemia and myelodysplasia compared to equally thrombocytopenic patients with immune thrombocytopenia. J Thromb Haemost. 2011;9(11):2302–2310. doi:10.1111/j.1538-7836.2011.04506.x.
   PubMed Web of Science ®Google Scholar
• Connor DE, Ma DD, Joseph JE. Flow cytometry demonstrates differences in platelet reactivity and microparticle formation in subjects with thrombocytopenia or thrombocytosis due to primary haematological disorders. Thromb Res. 2013;132(5):572–577. doi:10.1016/j.thromres.2013.09.009.
   PubMed Web of Science ®Google Scholar
• Barbui T, Finazzi G. Therapy for polycythemia vera and essential thrombocythemia is driven by the cardiovascular risk. Semin Thromb Hemost. 2007;33(4):321–329. doi:10.1055/s-2007-976166.
   PubMed Web of Science ®Google Scholar
• Elliott MA, Tefferi A. Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. Br J Haematol. 2005;128(3):275–290. doi:10.1111/bjh.2005.128.issue-3.
   PubMed Web of Science ®Google Scholar
• Passamonti F, Rumi E, Arcaini L, Boveri E, Elena C, Pietra D, Boggi S, Astori C, Bernasconi P, Varettoni M, et al. Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients. Haematologica. 2008;93(11):1645–1651. doi:10.3324/haematol.13346.
   PubMed Web of Science ®Google Scholar
• Rumi E, Cazzola M. How I treat essential thrombocythemia. Blood. 2016;128(20):2403–2414. doi:10.1182/blood-2016-05-643346.
   PubMed Web of Science ®Google Scholar
• Rumi E, Cazzola M. Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms. Blood. 2017;129(6):680–692. doi:10.1182/blood-2016-10-695957.
   PubMed Web of Science ®Google Scholar
• Schafer AI. Bleeding and thrombosis in the myeloproliferative disorders. Blood. 1984;64(1):1–12.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Elliott M. Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F. Semin Thromb Hemost. 2007;33(4):313–320. doi:10.1055/s-2007-976165.
   PubMed Web of Science ®Google Scholar
• Fenaux P, Simon M, Caulier MT, Lai JL, Goudemand J, Bauters F. Clinical course of essential thrombocythemia in 147 cases. Cancer. 1990;66(3):549–556. doi:10.1002/(ISSN)1097-0142.
   PubMed Web of Science ®Google Scholar
• Malpass TW, Savage B, Hanson SR, Slichter SJ, Harker LA. Correlation between prolonged bleeding time and depletion of platelet dense granule ADP in patients with myelodysplastic and myeloproliferative disorders. J Lab Clin Med. 1984;103(6):894–904.
   PubMed Web of Science ®Google Scholar
• Rendu F, Lebret M, Nurden A, Caen JP. Detection of an acquired platelet storage pool disease in three patients with a myeloproliferative disorder. Thromb Haemost. 1979;42(2):794–796.
   PubMed Web of Science ®Google Scholar
• Swart SS, Pearson D, Wood JK, Barnett DB. Functional significance of the platelet alpha2-adrenoceptor: studies in patients with myeloproliferative disorders. Thromb Res. 1984;33(5):531–541. doi:10.1016/0049-3848(84)90019-7.
   PubMed Web of Science ®Google Scholar
• Harrison CN. Platelets and thrombosis in myeloproliferative diseases. Hematology Am Soc Hematol Educ Program. 2005;409–415.
   PubMedGoogle Scholar
• Briere JB. Essential thrombocythemia. Orphanet J Rare Dis. 2007;2:3. doi:10.1186/1750-1172-2-3.
   PubMed Web of Science ®Google Scholar
• Falanga A, Marchetti M, Vignoli A, Balducci D, Barbui T. Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera. Exp Hematol. 2005;33(5):523–530. doi:10.1016/j.exphem.2005.01.015.
   PubMed Web of Science ®Google Scholar
• Jensen MK, de Nully Brown P, Lund BV, Nielsen OJ, Hasselbalch HC. Increased circulating platelet-leukocyte aggregates in myeloproliferative disorders is correlated to previous thrombosis, platelet activation and platelet count. Eur J Haematol. 2001;66(3):143–151. doi:10.1034/j.1600-0609.2001.00359.x.
   PubMed Web of Science ®Google Scholar
• Villmow T, Kemkes-Matthes B, Matzdorff AC. Markers of platelet activation and platelet-leukocyte interaction in patients with myeloproliferative syndromes. Thromb Res. 2002;108(2–3):139–145. doi:10.1016/S0049-3848(02)00354-7.
   PubMed Web of Science ®Google Scholar
• Avram S, Lupu A, Angelescu S, Olteanu N, Mut-Popescu D. Abnormalities of platelet aggregation in chronic myeloproliferative disorders. J Cell Mol Med. 2001;5(1):79–87. doi:10.1111/j.1582-4934.2001.tb00140.x.
   PubMed Web of Science ®Google Scholar
• Cesar JM, De Miguel D, Garcia Avello A, Burgaleta C. Platelet dysfunction in primary thrombocythemia using the platelet function analyzer, PFA-100. Am J Clin Pathol. 2005;123(5):772–777. doi:10.1309/K58EWK4HPD51U3BE.
   PubMed Web of Science ®Google Scholar
• Dragani A, Pascale S, Recchiuti A, Mattoscio D, Lattanzio S, Petrucci G, Mucci L, Ferrante E, Habib A, Ranelletti FO, et al. The contribution of cyclooxygenase-1 and −2 to persistent thromboxane biosynthesis in aspirin-treated essential thrombocythemia: implications for antiplatelet therapy. Blood. 2010;115(5):1054–1061. doi:10.1182/blood-2009-08-236679.
   PubMed Web of Science ®Google Scholar
• Rocca B, Ciabattoni G, Tartaglione R, et al. Increased thromboxane biosynthesis in essential thrombocythemia. Thromb Haemost. 1995;74(5):1225–1230.
   PubMed Web of Science ®Google Scholar
• Van Genderen PJ, Prins FJ, Michiels JJ, Schror K. Thromboxane-dependent platelet activation in vivo precedes arterial thrombosis in thrombocythaemia: a rationale for the use of low-dose aspirin as an antithrombotic agent. Br J Haematol. 1999;104(3):438–441. doi:10.1046/j.1365-2141.1999.01224.x.
   PubMed Web of Science ®Google Scholar
• Yamamoto K, Sekiguchi E, Takatani O. Abnormalities of epinephrine-induced platelet aggregation and adenine nucleotides in myeloproliferative disorders. Thromb Haemost. 1984;52(3):292–296.
   PubMed Web of Science ®Google Scholar
• Lussana F, Femia EA, Pugliano MT, Podda GM, Razzari C, Maugeri N, Lecchi A, Caberlon S, Gerli G, Cattaneo M. Evaluation of platelet function in essential thrombocythemia patients by light transmission and impedance aggregometry. 2018. Manuscript in preparation.
   Google Scholar
• Bermejo E, Alberto MF, Meschengieser SS, Lazzari MA. Assessment of platelet activation in myeloproliferative disorders with complementary techniques. Blood Coagul Fibrinolysis. 2004;15(3):235–240. doi:10.1097/00001721-200404000-00006.
   PubMed Web of Science ®Google Scholar
• Nurden P, Bihour C, Smith M, Raymond JM, Nurden AT. Platelet activation and thrombosis: studies in a patient with essential thrombocythemia. Am J Hematol. 1996;51(1):79–84. doi:10.1002/(ISSN)1096-8652.
   PubMed Web of Science ®Google Scholar
• Patrono C. The multifaceted clinical readouts of platelet inhibition by low-dose aspirin. J Am Coll Cardiol. 2015;66(1):74–85. doi:10.1016/j.jacc.2015.05.012.
   PubMed Web of Science ®Google Scholar
• Cattaneo M. P2Y12 receptors: structure and function. J Thromb Haemost. 2015;13(Suppl 1):S10–6. doi:10.1111/jth.12952.
   PubMedGoogle Scholar
• Cattaneo M. Response variability to clopidogrel: is tailored treatment, based on laboratory testing, the right solution? J Thromb Haemost. 2012;10(3):327–336. doi:10.1111/j.1538-7836.2011.04602.x.
   PubMed Web of Science ®Google Scholar
• Brar SS, ten Berg J, Marcucci R, Price MJ, Valgimigli M, Kim HS, Patti G, Breet NJ, DiSciascio G, Cuisset T, et al. Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data. J Am Coll Cardiol. 2011;58(19):1945–1954. doi:10.1016/j.jacc.2011.06.059.
   PubMed Web of Science ®Google Scholar
• Danese E, Fava C, Beltrame F, Tavella D, Calabria S, Benati M, Gelati M, Gottardo R, Tagliaro F, Guidi GC, et al. Relationship between pharmacokinetics and pharmacodynamics of clopidogrel in patients undergoing percutaneous coronary intervention: comparison between vasodilator-stimulated phosphoprotein phosphorylation assay and multiple electrode aggregometry. J Thromb Haemost. 2016;14:282–293.
   PubMed Web of Science ®Google Scholar
• Price MJ, Berger PB, Teirstein PS, Tanguay JF, Angiolillo DJ, Spriggs D, Puri S, Robbins M, Garratt KN, Bertrand OF, et al. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. Jama. 2011;305(11):1097–1105. doi:10.1001/jama.2011.290.
   PubMed Web of Science ®Google Scholar
• Collet JP, Cuisset T, Rangé G, Cayla G, Elhadad S, Pouillot C, Henry P, Motreff P, Carrié D, Boueri Z, et al. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med. 2012; 367(22):2100–2109. doi:10.1056/NEJMoa1209979.
   PubMed Web of Science ®Google Scholar
• Siller-Matula JM, Jilma B. Why have studies of tailored anti-platelet therapy failed so far? Thromb Haemost. 2013;110(4):628–631. doi:10.1160/TH13-03-0250.
   PubMed Web of Science ®Google Scholar
• Parodi G, Marcucci R, Valenti R, et al. High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI. Jama. 2011;306(11):1215–1223. doi:10.1001/jama.2011.1332.
   PubMed Web of Science ®Google Scholar
• Cayla G, Cuisset T, Silvain J, Leclercq F, Manzo-Silberman S, Saint-Etienne C, Delarche N, Bellemain-Appaix A, Range G, El Mahmoud R, et al. Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint, randomised controlled superiority trial. Lancet. 2016; 388(10055):2015–2022. doi:10.1016/S0140-6736(16)31323-X.
   PubMed Web of Science ®Google Scholar
• Mahla E, Suarez TA, Bliden KP, Rehak P, Metzler H, Sequeira AJ, Cho P, Sell J, Fan J, Antonino MJ, et al. Platelet function measurement based strategy to reduce bleeding and waiting time in clopidogrel-treated patients undergoing coronary artery bypass graft surgery: the timing based on platelet function strategy to reduce clopidogrel-associated bleeding related to CABG (TARGET-CABG) study. Circ Cardiovasc Interv. 2012;5:261–269.
   PubMed Web of Science ®Google Scholar
• Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, Jüni P, Kastrati A, Kolh P, Mauri L, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2017 Aug 26. doi:10.1093/eurheartj/ehx419.
   Google Scholar
• Morici N, Perna E, Cipriani M, Femia EA, Oliva F, Frigerio M, Cattaneo M. Ticagrelor for left ventricular assist device thrombosis: a new therapeutic option to be evaluated with caution. Int J Cardiol. 2016;221:58–59. doi:10.1016/j.ijcard.2016.06.304.
   PubMed Web of Science ®Google Scholar
• Podda GM, Grossi E, Palmerini T, Buscema M, Femia EA, Della Riva D, de Servi S, Calabrò P, Piscione F, Maffeo D, et al. Prediction of high on-treatment platelet reactivity in clopidogrel-treated patients with acute coronary syndromes. Int J Cardiol. 2017;240:60–65. doi:10.1016/j.ijcard.2017.03.074.
   PubMed Web of Science ®Google Scholar